Aedifica, Cofinimmo: Update on the Belgian Competition Authority. Arcadis: Share buyback programme. ASR: Focus on rural Real Estate – Farmland Fund. Coca-Cola Europacific Partners plc: Disasters strike. Heineken: From green to red. Zabka: Raising medium term store opening guidance
Aedifica provided an update on its pending transaction, confirming that it remains in the pre-notification phase with the Belgian Competition Authority (BCA). The company is in ongoing discussions with the BCA's Investigation and Prosecution Service (IPS), including around potential commitments such as asset disposals in Belgium. While the timeline for the formal filing has shifted, Aedifica still aims to launch the exchange offer in Q4 2025, subject to ending the pre-notification phase by end-O...
Arcadis just announced the start of a €175m SBB. At the current share price this represents a total of approximately 4m shares or 5% of the company's ordinary shares outstanding. We applaud this move which somewhat comes as a surprise. Earlier on it was repeatedly stated by the company that M&A was the preferred way of allocating capital even at Arcadis' low trading valuation. By repurchasing shares, Arcadis is creating value while remaining well within its target leverage range of 1.5x – 2.5x N...
Inventiva Appoints Andrew Obenshain as Chief Executive Officer Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Andrew Obenshain as Chief Executive Officer (“CEO”) of the Company. Mr. Obenshain will also join the Company’s Board of Directors. He succeeds Frédéric Cren, the Company’s co-founder...
Inventiva annonce la nomination d’Andrew Obenshain au poste de Directeur Général Daix (France), New York City (New York, Etats-Unis), le 1er octobre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce aujourd’hui la nomination d’Andrew Obenshain au poste de Directeur Général, à compter du 1er octobre 2025. M. Obenshain rejoindra également le Conseil d’administration de la Socié...
Over the past month, the EPRA BELUX index has underperformed (total return) the EPRA Developed Europe index by 3.2%, the STOXX50 by 5.4%, and the BEL20 by 3.6%. This underperformance relative to the EPRA Developed Europe Index can be attributed to the stronger performance of UK real estate compared to eurodenominated stocks, as UK equities led the recovery following a selloff in August. Additionally, the BELUX region had already posted strong year-to-date performance, which limited further upsid...
Arcadis announces €175 million share buyback program PRESS RELEASE Arcadis announces €175 million share buyback program Amsterdam, 1 October 2025 – Arcadis N.V. (Arcadis), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, today announced the start of a share buyback program under which it plans to repurchase ordinary shares of Arcadis for a maximum total value of €175 million. At the current share price this represents a total of approximately 4 million shares or 5% of the company’s ordinary shares o...
Arcadis shareholders appoint Simon Crowe as new CFO and member of the Executive Board PRESS RELEASE Arcadis’ shareholders appoint Simon Crowe as new CFO and member of the Executive Board Amsterdam, 30 September 2025 – Arcadis (EURONEXT: ARCAD), a global leader in sustainable design, engineering, and consultancy solutions, confirms the appointment of Simon Crowe for the position of Chief Financial Officer and member of the Executive Board. Simon Crowe was appointed to the Executive Board of Arcadis for a period of four years and will commence his role as CFO of Arcadis with immedi...
Inventiva reported 1H25 results which hold no surprises, and confirmed its cash runway guidance to the end of 3Q26 and timeline for the topline readout from the phase 3 (NATiV3) trial of lanifibranor in MASH, which continues to be guided for 2H26. We believe this readout is de-risked by strong phase 2b data, and with oral dosing and clean safety (limited GI side effects), lanifibranor is well positioned to capture a meaningful share of the validated MASH commercial opportunity. Given relative un...
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update Cash and cash equivalents at €146.7 million including €24.6 million in short-term deposits1 as of June 30, 2025Receipt of the gross proceeds of €115.6 million from the second tranche of the structured financing of up to €348 million2, following in particular the completion in April 2025 of enrolment of the Phase 3 clinical trial NATiV3 evaluating lanifibranor in patients with MASHCash runway currently planned until the end of the third quarter of 2026Revenues of €4.5 million recorded in the ...
Inventiva publie ses résultats financiers non audités du premier semestre 2025 et fait le point sur ses activités Trésorerie et équivalents de trésorerie à 122,1 millions d’euros et dépôts à court terme1 à 24,6 millions d’euros au 30 juin 2025Produit brut de 115,6 millions d’euros reçu au titre de la deuxième tranche du financement structuré pouvant atteindre 348 millions d’euros2, à la suite en particulier de la finalisation, en avril 2025, du recrutement pour l’étude clinique de Phase 3 NATiV3 évaluant le lanifibranor chez des patients atteints de MASHHorizon de trésorerie prévu jusqu’à l...
Aedifica: €21m investment in the development of 3 care homes in Finland. CTP: Highlights from 2-day CMD in Germany. dsm-firmenich: Softly does it. Prosus: Expanding the ecosystem. Randstad: Preliminary preview 3Q25F results due 22 October. TKH Group: Change is coming. UCB: Renewed tariff threat on US branded pharma unlikely to affect UCB
Inventiva to Host Analyst and Investor Event on October 8, 2025 Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026Three renowned international experts and a patient representative will highlight key trends shaping the MASH treatment landscape Daix (France), New York City (New York, United States), September 24, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.